Statements (16)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:mitapivat
|
| gptkbp:approvalYear |
2022
|
| gptkbp:ATCCode |
V03AX05
|
| gptkbp:form |
gptkb:tablet
|
| gptkbp:indication |
pyruvate kinase deficiency
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Agios_Pharmaceuticals
|
| gptkbp:mechanismOfAction |
pyruvate kinase activator
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
FDA approved
|
| gptkbp:targetAudience |
adults
children |
| gptkbp:bfsParent |
gptkb:Agios_Pharmaceuticals
|
| gptkbp:bfsLayer |
5
|
| https://www.w3.org/2000/01/rdf-schema#label |
PYRUKYND
|